Novo Nordisk A/S ADR (NVO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2024 | 12-2023 | 09-2023 | 06-2023 | 03-2023 | |
| Sales | 9,514,814 | 9,526,155 | 8,574,726 | 7,933,230 | 7,690,185 |
| Cost of Goods | 1,443,770 | 1,448,192 | 1,418,098 | 1,147,762 | 1,179,026 |
| Gross Profit | 8,071,045 | 8,077,962 | 7,156,628 | 6,785,468 | 6,511,159 |
| Operating Expenses | 3,435,037 | 4,207,256 | 3,227,428 | 3,296,193 | 2,907,676 |
| Operating Income | 4,636,778 | 3,870,901 | 3,929,298 | 3,490,037 | 3,603,509 |
| Interest Expense | 301,974 | -260,988 | 316,528 | -94,527 | 161,680 |
| Other Income | 312,457 | -138,534 | 484,428 | -41,054 | 122,773 |
| Pre-tax Income | 4,647,261 | 3,993,355 | 4,097,198 | 3,543,510 | 3,564,602 |
| Income Tax | 948,002 | 818,001 | 815,410 | 705,079 | 709,404 |
| Net Income Continuous | 3,699,259 | 3,175,355 | 3,281,788 | 2,838,431 | 2,855,198 |
| Net Income | $3,699,259 | $3,175,355 | $3,281,788 | $2,838,431 | $2,855,198 |
| EPS Basic Total Ops | 0.83 | 0.71 | 0.73 | 0.63 | 0.64 |
| EPS Basic Continuous Ops | 0.83 | 0.71 | 0.73 | 0.63 | 0.63 |
| EPS Diluted Total Ops | 0.83 | 0.71 | 0.73 | 0.63 | 0.63 |
| EPS Diluted Continuous Ops | 0.83 | 0.71 | 0.73 | 0.63 | 0.63 |
| EPS Diluted Before Non-Recurring Items | N/A | 0.71 | 0.73 | 0.63 | 0.64 |
| EBITDA(a) | $5,061,056 | $4,300,201 | $4,297,558 | $3,811,534 | $3,851,217 |